LIGAND PHARMACEUTICALS INCORPORATED Available-for-sale Securities, Amortized Cost Basis
LIGAND PHARMACEUTICALS INCORPORATED (LGND) had Available-for-sale Securities, Amortized Cost Basis of $212.12 million as of 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAmortizedCost · last filed 2018-05-09
- 2018-03-31: Available-for-sale Securities, Amortized Cost Basis $212.12M.
- 2017-12-31: Available-for-sale Securities, Amortized Cost Basis $179.53M.
- 2017-09-30: Available-for-sale Securities, Amortized Cost Basis $167.06M.
- 2017-06-30: Available-for-sale Securities, Amortized Cost Basis $110.38M.
| Period end | Available-for-sale Securities, Amortized Cost Basis |
|---|---|
| 2018-03-31 | $212.12M 10-Q · filed 2018-05-09 |
| 2017-12-31 | $179.53M 10-Q · filed 2018-05-09 |
| 2017-09-30 | $167.06M 10-Q · filed 2017-11-09 |
| 2017-06-30 | $110.38M 10-Q · filed 2017-08-09 |
| 2017-03-31 | $146.63M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $120.76M 10-Q · filed 2017-11-09 |
| 2016-09-30 | $34.53M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $42.27M 10-Q · filed 2016-11-14 |
| 2016-03-31 | $78.92M 10-Q · filed 2016-11-14 |
| 2015-12-31 | $97.89M 10-Q · filed 2016-11-14 |
| 2015-09-30 | $88.57M 10-Q · filed 2015-11-09 |
| 2015-06-30 | $62.70M 10-Q · filed 2015-08-05 |
| 2014-12-31 | $3.44M 10-K · filed 2016-11-14 |